Deep Polymers manufactures masterbatches and polymer additives used to color and enhance the properties of plastic products for industries ranging from packaging to textiles.
The company operates in a fragmented, commodity-like market with no evidence of a moat; low net margins of 5% and a ROCE of 10.8% suggest a lack of pricing power or cost advantage. While they claim market leadership, the financials reflect a price-taker in a competitive industry.
Capital has been deployed into capacity expansion and property, plant, and equipment, but EPS has remained flat over several years despite revenue growth. The company recently issued shares to promoters via preferential allotment while maintaining a conservative debt profile.
The investment collapsed as the refusal to write off 316.72 Lacs in doubtful debts eventually forced a massive, sudden restatement that wiped out years of reported earnings. The lack of internal controls and audit trail gaps allowed operational inefficiencies to fester, while the appointment of an inexperienced teenager to the board signaled a total abandonment of meritocracy. As the commodity cycle turned, the company’s lack of pricing power and flat EPS growth despite capital expenditure led to a permanent de-rating, with the auditor's resignation serving as the final warning before the market realized the reported assets were largely illusory.
RichFakir rates Deep Polymers Ltd's business quality as poor — 22/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Deep Polymers Ltd is trading about 69% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Deep Polymers Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Deep Polymers Ltd's fair value is about ₹20 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →